Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

NuVasive's Monolith Corpectomy System Ok'd for Expanded Use

NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.

Hill-Rom Adds New Capabilities to Centrella Smart+ Beds

Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.

Varian Medical ProBeam-Equipped Emory Center Opens in Georgia

Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

Myriad Genetics (MYGN) see strong testing volumes from new products.

Baxter & EFCNI Collaborate to Improve Care for Preterm Born

Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.

Here's Why You Should Invest in athenahealth (ATHN) Now

A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.

Illumina (ILMN) Takes Part in NIH Program With Genotype Launch

The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

A strong international presence and strategic buyouts aid Varian Medical (VAR); margins pressed.

Quest Diagnostics Rides on Product Launches, Strategic Deals

Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.

STERIS (STE) Dips on New Restructuring Plan, Layoff Decision

STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.

Here's Why You Should Invest in Veeva Systems (VEEV) Now

A solid fiscal third quarter and a plethora of recent developments make Veeva Systems (VEEV) a promising investment pick.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

Chemed's (CHE) subsidiaries continue to register strong sales.

ResMed to Buy Propeller Health, Widens Respiratory Care Suite

Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.

Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds

Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.

Genomic Health (GHDX), BioCartis Extend Deal to Urology

The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.

Zimmer Biomet Rides on New Operational Plan Amid Several Woes

In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.

LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance

Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Omnicell (OMCL) continues to witness strong conversion wins for new XT series.

CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing

The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.

QIAGEN's New Offerings to Broaden Hematology Testing Suite

QIAGEN (QGEN) continues to progress with test menu expansion.

Here's Why You Should Invest in Surmodics (SRDX) Right Now

A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.

Varian Medical's (VAR) Halcyon Gets NMPA Approval in China

Varian Medical (VAR) enjoys significant international presence in radiotherapy.